- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Volrustomig, FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan), Bevacizumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 943
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Solid Tumor
- Interventions
- Epacadostat, Pembrolizumab, Oxaliplatin, Leucovorin, 5-Fluorouracil, Gemcitabine, nab-Paclitaxel, Carboplatin, Paclitaxel, Pemetrexed, Cyclophosphamide, Cisplatin, Investigator's choice of platinum agent
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 12 more
- Conditions
- Colorectal Neoplasms
- Interventions
- 5-fluorouracil
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Carcinoma, Endometrial Adenocarcinoma, Neoplasms, Squamous Cell Carcinoma of the Anus, Adenocarcinoma of the Pancreas, Advanced Cancer, Solid Tumor, Solid Carcinoma, Squamous Cell Carcinoma of the Cervix, Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Vulva, Squamous Cell Carcinoma of the Penis, Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small-cell Lung Cancer, Small Cell Lung Carcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma
- Interventions
- PEN-866 Sodium, fluorouracil, Folinic acid, Niraparib
- Drug
- Lead sponsor
- Tarveda Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 16
- States / cities
- Springdale, Arkansas • Denver, Colorado • Fort Myers, Florida + 13 more
- Conditions
- Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
- Interventions
- Fluorouracil, Irinotecan Sucrosofate, Laboratory Biomarker Analysis, Leucovorin Calcium, Rucaparib
- Drug · Other
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota
- Conditions
- Bladder Cancer, Urethral Cancer, Urachal Cancer
- Interventions
- 5-Fluorouracil (5-FU), Leucovorin, Cisplatin, Gemcitabine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Metastasis, HER-2 Gene Amplification
- Interventions
- Oxaliplatin, Leucovorin, 5 fluorouracil, Trastuzumab, Avelumab
- Drug
- Lead sponsor
- Ashwin Somasundaram
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 7
- States / cities
- Duarte, California • Atlanta, Georgia • Chicago, Illinois + 4 more
- Conditions
- Leukemia
- Interventions
- filgrastim, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, mesna, methotrexate, therapeutic hydrocortisone, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET photon therapy
- Biological · Drug · Radiation
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2001
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Toxoplasmosis, Cerebral, HIV Infections
- Interventions
- Sulfadiazine, Clarithromycin, Atovaquone, Pyrimethamine, Leucovorin calcium
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1998
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Miami, Florida • Honolulu, Hawaii + 8 more
- Conditions
- Lymphoma
- Interventions
- rituximab, bendamustine hydrochloride, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, leucovorin calcium, methotrexate, vincristine sulfate
- Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2021
- U.S. locations
- 204
- States / cities
- Duarte, California • Aurora, Colorado • Boulder, Colorado + 142 more
- Conditions
- Pancreatic Cancer
- Interventions
- FOLFIRINOX, Intensity-modulated radiotherapy (IMRT), Surgical Exploration
- Drug · Radiation · Procedure
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
- Interventions
- Alcestobart, Tislelizumab, Bevacizumab or Bevacizumab biosimilar, Fluoropyrimidine (FP)
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 30
- States / cities
- Anchorage, Alaska • Gilbert, Arizona • Cerritos, California + 23 more
- Conditions
- Stomach Cancer, Gastric Cancer
- Interventions
- 5-Fluorouracil, Folinic Acid, Oxaliplatin, Radiotherapy, Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- modified FOLFIRINOX, Pentamidine 300 MG Injection
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- oxaliplatin, leucovorin calcium, fluorouracil, capecitabine, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Lymphoma
- Interventions
- asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, leucovorin calcium, mercaptopurine, methotrexate, prednisone, thioguanine, vincristine sulfate, radiation therapy
- Drug · Radiation
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 393 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2015
- U.S. locations
- 152
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 127 more
- Conditions
- Breast Cancer, Ovarian Cancer, Colon Cancer, Lung Cancer, Gastric Cancer, Solid Tumors
- Interventions
- Veliparib, Carboplatin, Paclitaxel, FOLFIRI
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 2
- States / cities
- Scottsdale, Arizona • San Antonio, Texas
- Conditions
- Gastric Cancer, Stomach Cancer
- Interventions
- Potentially curative surgery, Floxuridine (IP), Adjuvant Chemoradiation therapy
- Procedure · Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 3
- States / cities
- New York, New York
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- bortezomib, fluorouracil, leucovorin calcium, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Central Nervous System Lymphoma
- Interventions
- Methotrexate, Rituximab, leucovorin, Glucarpidase
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Boston, Massachusetts • Basking Ridge, New Jersey + 8 more
- Conditions
- Acute Lymphocytic Leukemia
- Interventions
- aminopterin, L-asparaginase, cyclophosphamide, cytarabine, daunomycin, dexamethasone, 6-mercaptopurine, methotrexate, 6-thioguanine, vincristine, Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone), Leucovorin
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 2
- States / cities
- Neptune City, New Jersey • New Brunswick, New Jersey
- Conditions
- Lymphoma, Neoplasms
- Interventions
- 5-Fluorouracil, Ethynyluracil, Leucovorin
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
- Interventions
- Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Echocardiography Test, FDG-Positron Emission Tomography, Leucovorin, Levoleucovorin, Lumbar Puncture, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Methylprednisolone, Multigated Acquisition Scan, Prednisolone, Prednisone, Therapeutic Hydrocortisone, Thioguanine, Venetoclax, Vincristine
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 365 Days
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 115
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 100 more
- Conditions
- Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer
- Interventions
- gemcitabine hydrochloride, leucovorin calcium, fluorouracil, nelfinavir mesylate, stereotactic body radiation therapy, hypofractionated radiation therapy, therapeutic conventional surgery
- Drug · Radiation · Procedure
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska